|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:antineoplastic_agent
gptkb:anthracenedione
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedBy
|
gptkb:European_Union
|
|
gptkbp:ATCCode
|
L01DB18
|
|
gptkbp:brand
|
gptkb:Pixuvri
|
|
gptkbp:CASNumber
|
144510-96-3
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:developedBy
|
Cell Therapeutics, Inc.
|
|
gptkbp:drugClass
|
antitumor antibiotics
anthracenediones
|
|
gptkbp:hasMolecularFormula
|
C14H15N5O2
|
|
gptkbp:hasSMILES
|
CC(C)NCCN1C2=CC(=O)C3=C(C2=O)C=C(C=C3N(CCN(C)C)C)C1=O
|
|
gptkbp:IUPACName
|
1,4-dihydroxy-5,8-bis[2-(2-methylethylamino)ethylamino]anthracene-9,10-dione
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
DNA intercalation
topoisomerase II inhibition
|
|
gptkbp:PubChem_CID
|
6918493
CHEMBL1201832
5293772
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
alopecia
infections
neutropenia
cardiotoxicity
myelosuppression
|
|
gptkbp:synonym
|
gptkb:Pixuvri
BBR 2778
BBR-2778
|
|
gptkbp:UNII
|
6J8OL0BA3D
|
|
gptkbp:usedFor
|
gptkb:leukemia
|
|
gptkbp:bfsParent
|
gptkb:Servier_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pixantrone
|